Compass Therapeutics (CMPX) Total Current Liabilities (2018 - 2026)
Compass Therapeutics recorded quarterly Total Current Liabilities of $10.3 million in Q1 2026, down 26.41% quarter-over-quarter from $14.0 million in Q4 2025, and down 31.01% year-over-year from $14.9 million in Q1 2025.
Compass Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $10.3 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 31.01% year-over-year to $10.3 million; the TTM figure through Mar 2026 stood at $10.3 million (down 31.01% YoY), while the FY2025 annual figure was $14.0 million, up 57.4% from the prior year.
- Total Current Liabilities came in at $10.3 million for Q1 2026 at Compass Therapeutics, down from $14.0 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $16.2 million in Q4 2022 to a low of $3.9 million in Q1 2024.
- A 5-year average of $10.3 million and a median of $9.7 million in 2023 frame the typical range for Total Current Liabilities.
- Across the five-year window, Total Current Liabilities tumbled 65.21% in 2024 and jumped 282.74% in 2025, its largest moves.
- Compass Therapeutics' Total Current Liabilities stood at $16.2 million in 2022, then sank by 51.75% to $7.8 million in 2023, then rose by 13.75% to $8.9 million in 2024, then jumped by 57.4% to $14.0 million in 2025, then declined by 26.41% to $10.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $10.3 million, $14.0 million, and $12.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.70 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 636.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 66.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 13.42 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 3.88 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 5.11 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.35 Bn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - | 10.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.28 Mn |
| Dec 31, 2025 | 13.97 Mn |
| Sep 30, 2025 | 12.41 Mn |
| Jun 30, 2025 | 13.86 Mn |
| Mar 31, 2025 | 14.90 Mn |
| Dec 31, 2024 | 8.87 Mn |
| Sep 30, 2024 | 4.43 Mn |
| Jun 30, 2024 | 9.51 Mn |
| Mar 31, 2024 | 3.89 Mn |
| Dec 31, 2023 | 7.80 Mn |
| Sep 30, 2023 | 9.12 Mn |
| Jun 30, 2023 | 9.70 Mn |
| Mar 31, 2023 | 11.19 Mn |
| Dec 31, 2022 | 16.17 Mn |
| Sep 30, 2022 | 9.58 Mn |
| Jun 30, 2022 | 10.88 Mn |
| Mar 31, 2022 | 9.33 Mn |
| Dec 31, 2021 | 10.63 Mn |
| Sep 30, 2021 | 7.68 Mn |
| Mar 31, 2021 | 10.85 Mn |
| Dec 31, 2020 | 10.10 Mn |
| Sep 30, 2020 | 9.67 Mn |
| Jun 30, 2020 | 11.61 Mn |
| Mar 31, 2020 | 111,817.00 |
| Dec 31, 2019 | 9.82 Mn |
| Sep 30, 2019 | 91,336.00 |
| Jun 30, 2019 | 86,917.00 |
| Mar 31, 2019 | 75,455.00 |
| Dec 31, 2018 | 66,403.00 |
| Sep 30, 2018 | 54,028.00 |
| Jun 30, 2018 | 50,257.00 |
| Mar 31, 2018 | 34,577.00 |